TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30453487
Drug: Control yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control yogurt fermented with Streptococcus thermophiles, Lactobacillus delbrueckii subspecies bulgaricus, and Lactobacillus acidophilus, 80 g daily for 8 weeks
Study: 26723083
Drug: Anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-thymocyte globulin (ATG) 4.5 mg/kg intravenously over 3 days (0.5 mg/kg 2 days before transplantation, 2.0 mg/kg 1 day before, and 2.0 mg/kg 1 day after)
Study: 20400411
Drug: Vicriviroc (VCV)
Normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc (VCV) 5, 10, or 15 mg
Study: 15973115
Drug: 5‐ASA 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐ASA 500 mg suppository (Canasa; Axcan Pharma) BID
Study: 15973115
Drug: 5‐ASA 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐ASA 1 g at bedtime (HS)
Study: 14636777
Drug: Antiepileptic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic treatment for transitory cognitive impairment (TCI)
Study: 8633817
Drug: 3600 mg
Normalized name: Ascorbic Acid/Calcium 3600 MG-400 MG Oral Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3600 mg saquinavir per day
Study: 8633817
Drug: 7200 mg
Normalized name: chymotrypsin 7200 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7200 mg saquinavir per day
Study: 9259838
Drug: Antithrombin replacement
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin replacement therapy
Study: 6414283
Drug: Commercial starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial starch blocker
Study: 31443654
Drug: Single-dose azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose azithromycin (20 mg/kg)
Study: 24708443
Drug: Long-term oral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oral corticosteroids (LTOC)
Study: 21643774
Drug: V0355 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: V0355 (80 mg Fe/day)
Study: 21643774
Drug: Ferrograd® (105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrograd® (105 mg Fe/day)
Study: 9808644
Drug: 720 mL/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 720 mL/d of apple juice containing 5 g of gum arabic and pectin (4:1 ratio)
Study: 9808644
Drug: 720 mL/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 720 mL/d of apple juice containing 9 g of gum arabic and pectin (4:1 ratio)
Study: 9808644
Drug: 720 mL/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 720 mL/d of apple juice containing 15 g of gum arabic and pectin (4:1 ratio)
Study: 9808644
Drug: 720 mL/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 720 mL/d of apple juice (control)
Study: 7631621
Drug: bisoprolol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol (2.5 to 10 mg) with 6.25 mg of hydrochlorothiazide (HCTZ)
Study: 7631621
Drug: amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine (2.5 to 10 mg)
Study: 7631621
Drug: enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril (5 to 20 mg)
Study: 7346529
Drug: H-1 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H-1 antagonist hydroxyzine
Study: 7346529
Drug: H-2 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H-2 antagonist cimetidine
Study: 7346529
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of H-1 and H-2 antagonists
Study: 31305270
Drug: Pertuzumab (840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertuzumab (840 mg loading dose followed by 420 mg maintenance doses every 3 weeks)
Study: 31305270
Drug: Pertuzumab (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertuzumab (in combination with trastuzumab)
Study: 27025843
Drug: IV aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV aminophylline (100 mg administered over 30-60 seconds)
Study: 27025843
Drug: IV caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV caffeine citrate (60 mg infused over 3-5 minutes)
Study: 19786379
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg lutein/d
Study: 19786379
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg lutein/d
Study: 17538165
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus capecitabine (GemCap) - oral capecitabine 650 mg/m2 twice daily on days 1 to 14 plus Gem 1,000 mg/m2 by 30‐minute infusion on days 1 and 8 every 3 weeks
Study: 17538165
Drug: Gemcitabine (Gem)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (Gem) - 1,000 mg/m2 by 30‐minute infusion weekly for 7 weeks, followed by a 1‐week break, and then weekly for 3 weeks every 4 weeks
Study: 16566943
Drug: Pulse low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse low doses of methylprednisolone (250 mg given twice IV)
Study: 14527736
Drug: Second-generation antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antihistamines with combined topical corticosteroid treatment (Group 1)
Study: 14527736
Drug: Second-generation antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antihistamines without steroid treatment (Group 2)
Study: 14527736
Drug: Second-generation antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antihistamines (both groups)
Study: 10790990
Drug: Stimulants (MPH,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulants (MPH, DEX, pemoline)
Study: 10790990
Drug: Tricyclic antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressants (desipramine, imipramine)
Study: 10790990
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies (stimulant or nondrug intervention)
Study: 10790990
Drug: Stimulants vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulants vs. placebo
Study: 10790990
Drug: Adverse effects
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse effects of drug therapy
Study: 10790990
Drug: Long-term therapy
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term therapy (> or = 12 weeks)
Study: 10790990
Drug: Academic performance
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Academic performance with stimulants
Study: 8932964
Drug: Standard antidepressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antidepressants (imipramine, fluoxetine, sertraline)
Study: 1989742
Drug: Local anaesthesia
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthesia combined with light sedation (midazolam 0.1 mg.kg‐1 and alfentanil 0 micrograms.kg‐1)
Study: 1989742
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia (propofol 2.5 mg.kg‐1, then 9 mg.kg‐1.hr‐1 and alfentanil 30 micrograms.kg‐1, then 15 micrograms.kg‐1)
Study: 25560571
Drug: Vildagliptin 100mg
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin 100mg plus metformin
Study: 23842505
Drug: CR® neuromodulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR® neuromodulation therapy
Study: 20863217
Drug: L-Carnitine 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Carnitine 1000 mg/day for 12 weeks
Study: 18195111
Drug: ABCC2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ABCC2 inhibitor probenecid
Study: 18195111
Drug: Nonspecific inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific inhibitor verapamil
Study: 18195111
Drug: ABCB1 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ABCB1 inhibitor valspodar (PSC833)
Study: 12571548
Drug: Placebo-CPAP (CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-CPAP (CPAP administered at ineffective pressure)
Study: 10596415
Drug: Bifidobacteria (Töpfer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacteria (Töpfer Bifidus) administered via nasogastral tube, initial dosage of 3 times daily 1.25 x 10(8) bifidobacteria on day 2, then 6 times daily 1.25 x 10(8) bifidobacteria on day 3 until day 21
Study: 28196063
Drug: dCRT (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: dCRT (cisplatin 60 mg/m² on day 1 and capecitabine 625 mg/m² bd on days 1-21 for four cycles)
Study: 28196063
Drug: dCRT+C (dCRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: dCRT+C (dCRT plus cetuximab 400 mg/m² on day 1 then 250 mg/m² weekly)
Study: 26398851
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg for 8 weeks
Study: 19743466
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) 1,500mg daily
Study: 12612146
Drug: Daily supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplement (272 mg vitamin C, 31 mg all‐rac‐alpha‐tocopherol, and 400 micro g folic acid) for 90 days
Study: 1556292
Drug: Religious Cognitive-Behavioral
Normalized name: red delicious apple allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Religious Cognitive-Behavioral Therapy (RCT)
Study: 1556292
Drug: Nonreligious Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonreligious Cognitive-Behavioral Therapy (NRCT)
Study: 1556292
Drug: Pastoral Counseling
Normalized name: castoryl maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pastoral Counseling Treatment-as-Usual (PCT)
Study: 31362785
Drug: Local ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local ice cryotherapy (30 min applied twice during 1 day at an 8-h interval)
Study: 31362785
Drug: Cold CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold CO2 (2 min applied twice during 1 day at an 8-h interval)
Study: 19638799
Drug: Weekly visits
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly visits with WCSs (Group B)
Study: 16978805
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with prebiotic fructo-oligosaccharides at a concentration of 0.4 g/dL
Study: 2205292
Drug: Vitamin-mineral supplement
Normalized name: Prenatal Vitamins Oral Tablet [PRENATAL VITAMIN-MINERAL SUPPLEMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-mineral supplement daily for 28 days
Study: 2205292
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 28 days
Study: 26141142
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to antipsychotic monotherapy
Study: 21612469
Drug: Albuterol followed
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol followed by methacholine (control)
Study: 16722829
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg primaquine with food
Study: 16722829
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg primaquine with grapefruit juice
Study: 16722829
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg primaquine in fasting state
Study: 8686522
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg morphine and 2.5 mg dehydrobenzperidol (DHB) in 10 ml physiological saline
Study: 8686522
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg morphine and 0.1 mg fentanyl in 10 ml physiological saline
Study: 27857189
Drug: Repaglinide (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (oral administration for 8 weeks)
Study: 27857189
Drug: Repaglinide with
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide with KCNQ1 inhibitor
Study: 24075865
Drug: Laparoscopic cystectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic cystectomy by stripping with saline injection (saline group)
Study: 24075865
Drug: Laparoscopic cystectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic cystectomy by stripping with vasopressin injection technique (VIT group)
Study: 24075865
Drug: Laparoscopic cystectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic cystectomy by stripping without injection (control group)
Study: 20113339
Drug: Pregabalin 150-600
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150-600 mg/day (dosed twice daily)
Study: 16271654
Drug: Telephone psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone psychotherapy program (TPP) during maintenance-phase treatment (6-12 months).
Study: 12499212
Drug: lopinavir/ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir 400/100 mg BID
Study: 12499212
Drug: lopinavir/ritonavir 533/133
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir 533/133 mg BID
Study: 30464128
Drug: Combined thrombus
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined thrombus burden reduction therapy
Study: 30248056
Drug: Personalized neurofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized neurofeedback cognitive training using the BRAINMEM system, comprising 24 sessions over eight weeks and three monthly booster sessions.
Study: 24445833
Drug: Inactivated control
Normalized name: hepatitis A virus strain CR 326F antigen, inactivated Injection [Vaqta]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated control trivalent influenza vaccines (TIVs) containing Victoria-lineage B strain
Study: 24445833
Drug: Inactivated control
Normalized name: hepatitis A virus strain CR 326F antigen, inactivated Injection [Vaqta]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated control trivalent influenza vaccines (TIVs) containing Yamagata-lineage B strain
Study: 21916952
Drug: Mandibular overdenture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdenture retained by two splinted implants with bar-clip system
Study: 20082624
Drug: Glipizide controlled-release
Normalized name: glipizide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide controlled-release (CR) tablets monotherapy
Study: 20082624
Drug: Glipizide controlled-release
Normalized name: glipizide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide controlled-release (CR) tablets plus acarbose
Study: 8652324
Drug: modified fluid
Normalized name: modified fluid gelatin
DrugBank: Succinylated gelatin (DB16568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified fluid gelatin (Gel)
Study: 1647149
Drug: Cisplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (80 mg/m2, day 1)/Etoposide (100 mg/m2, day 1, 3, 5) (PE)
Study: 1647149
Drug: Cisplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (80 mg/m2, day 1)/Etoposide (100 mg/m2, day 1, 3, 5)/Ifosfamide (2 g/m2, day 1, 2, 3) (PEI)
Study: 22652942
Drug: Prednisolone, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone, 60 mg/d for 5 days, tapered for 5 days
Study: 16204002
Drug: Severe leucopenia
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe leucopenia during chemotherapy
Study: 16204002
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who developed severe leucopenia within the first two cycles of chemotherapy
Study: 12352809
Drug: Birth dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birth dose of HepB
Study: 12352809
Drug: No birth
Approvals — FDA: no, EMA: no, PMDA: no
Description: No birth dose of HepB
Study: 2236929
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate 500 micrograms daily
Study: 2236929
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate 1,000 micrograms daily
Study: 406627
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg methylphenidate
Study: 406627
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg methylphenidate (open trial)
Study: 30379568
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of first-line chemotherapy
Study: 24638908
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with long‐chain ω‐3 polyunsaturated fatty acids (350 mg DHA + 650 mg EPA)
Study: 24638908
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with lutein + zeaxanthin (10 mg lutein + 2 mg zeaxanthin)
Study: 24638908
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of long‐chain ω‐3 fatty acids and lutein + zeaxanthin
Study: 23651231
Drug: N-acetylcysteine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (800 mg/day)
Study: 12680858
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (3.7 g n-3 PUFA/day)
Study: 10887922
Drug: 0.01% all‐trans‐retinoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% all‐trans‐retinoic acid (tretinoin) ophthalmic emulsion
Study: 9197524
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (50 or 500 mg/day) for 5 years
Study: 9197524
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (0 or 15 mg/day) for 5 years (discontinued after initial recruitment)
Study: 8110565
Drug: Extradural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural morphine 0.75 microgram kg‐1 with an additional dose administered 24 h later (group M)
Study: 8110565
Drug: Extradural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Extradural fentanyl 2 micrograms kg‐1 followed by continuous extradural infusion of fentanyl 5 micrograms kg‐1 day‐1 (group F)
Study: 8110565
Drug: Continuous extradural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous extradural infusion of fentanyl 5 micrograms kg‐1 day‐1
Study: 24412895
Drug: Methotrexate and
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate and intra-articular glucocorticosteroid injections with adalimumab
Study: 24412895
Drug: Methotrexate and
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate and intra-articular glucocorticosteroid injections with placebo
Study: 8831082
Drug: Prophylactic fresh
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic fresh frozen plasma (20 ml/kg followed by 10 ml/kg after 24 h)
Study: 8831082
Drug: Control management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control management with a maintenance infusion of 10% dextrose
Study: 1282183
Drug: 10 or
Normalized name: K-10 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 or 20 mg nicorandil
Study: 4040500
Drug: OKY‐1581 (thromboxane
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKY‐1581 (thromboxane A2 synthetase inhibitor); 2-3 micrograms/kg per min for 48 hours
Study: 4040500
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment with OKY‐1581)
Study: 4040500
Drug: OKY‐1581 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKY‐1581 treatment
Study: 24685536
Drug: Therapist-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-delivered cognitive behavioural therapy session (CB-Education)
Study: 19435959
Drug: Fenofibrate +
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate + Metformin
Study: 11685031
Drug: Erythromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (1 mg/kg every 8 hours for 14 days)
Study: 11685031
Drug: Control (H2-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (H2-receptor antagonists and gastrokinetic drugs)
Study: 2239303
Drug: VP-16 combined
Normalized name: etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: VP-16 combined with other anti-tumor agents
Study: 19267963
Drug: Matched-taper single-cone
Normalized name: Pinus strobus cone extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched-taper single-cone obturation
Study: 17112804
Drug: Ezetimibe (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (20 mg orally)
Study: 11248608
Drug: Tolterodine IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine IR 2 mg twice daily
Study: 11248608
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER 4 mg once daily and Tolterodine IR 2 mg twice daily
Study: 9227717
Drug: Pranlukast, 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast, 450 mg twice daily
Study: 8039526
Drug: Active approach
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active approach to pharmacological treatment